PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 04: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 06: PIPELINE ANALYSIS PART 07: MARKET SEGMENTATION BY PRODUCT • Market segmentation by product • Comparison by product • Small molecules - Market size and forecast 2018-2023 • Biologics - Market size and forecast 2018-2023 • Market opportunity by product PART 08: CUSTOMER LANDSCAPE PART 09: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • North America - Market size and forecast 2018-2023 • Europe - Market size and forecast 2018-2023 • Asia - Market size and forecast 2018-2023 • ROW - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 10: DECISION FRAMEWORK PART 11: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 12: MARKET TRENDS • Identification of new pathogenic targets • Identification of new drug targets for atherosclerosis • Strong incidence of coronary heart disease (CHD) PART 13: VENDOR LANDSCAPE • Overview • Landscape disruption • Competitive scenario PART 14: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • AstraZeneca Plc • Bayer AG • Merck & Co. Inc. • Novartis AG • Sanofi PART 15: APPENDIX • Research methodology • List of abbreviations • Definition of market positioning of vendors PART 16: EXPLORE TECHNAVIO   Exhibit 01: Product overview Exhibit 02: Global pharmaceuticals market Exhibit 03: Segments of global pharmaceuticals market Exhibit 04: Market characteristics Exhibit 05: Market segments Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2018 Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 09: Hypothesis behind LDL deposition in intima Exhibit 10: Global market: Year-over-year growth 2019-2023 (%) Exhibit 11: Five forces analysis 2018 Exhibit 12: Five forces analysis 2023 Exhibit 13: Bargaining power of buyers Exhibit 14: Bargaining power of suppliers Exhibit 15: Threat of new entrants Exhibit 16: Threat of substitutes Exhibit 17: Threat of rivalry Exhibit 18: Market condition - Five forces 2018 Exhibit 19: Some of the key clinical trials in global atherosclerosis therapeutics market Exhibit 20: Product - Market share 2018-2023 (%) Exhibit 21: Comparison by product Exhibit 22: Small molecules - Market size and forecast 2018-2023 ($ millions) Exhibit 23: Small molecules - Year-over-year growth 2019-2023 (%) Exhibit 24: Biologics - Market size and forecast 2018-2023 ($ millions) Exhibit 25: Biologics - Year-over-year growth 2019-2023 (%) Exhibit 26: Market opportunity by product Exhibit 27: Customer landscape Exhibit 28: Market share by geography 2018-2023 (%) Exhibit 29: Geographic comparison Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 31: Adoption rate of health insurance coverage among US adults with CHD, or a stroke, or both, 2019 Exhibit 32: North America - Year-over-year growth 2019-2023 (%) Exhibit 33: Top 3 countries in North America Exhibit 34: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 35: Europe - Year-over-year growth 2019-2023 (%) Exhibit 36: Top 3 countries in Europe Exhibit 37: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 38: Asia - Year-over-year growth 2019-2023 (%) Exhibit 39: Top 3 countries in Asia Exhibit 40: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 41: ROW - Year-over-year growth 2019-2023 (%) Exhibit 42: Top 3 countries in ROW Exhibit 43: Key leading countries Exhibit 44: Market opportunity Exhibit 45: Impact of drivers and challenges Exhibit 46: Incidence rate of CHD in adults aged 45 years and above 2019 Exhibit 47: Vendor landscape Exhibit 48: Landscape disruption Exhibit 49: Vendors covered Exhibit 50: Vendor classification Exhibit 51: Market positioning of vendors Exhibit 52: AstraZeneca Plc - Vendor overview Exhibit 53: AstraZeneca Plc - Business segments Exhibit 54: AstraZeneca Plc - Organizational developments Exhibit 55: AstraZeneca Plc - Geographic focus Exhibit 56: AstraZeneca Plc - Key offerings Exhibit 57: AstraZeneca Plc - Key customers Exhibit 58: Bayer AG - Vendor overview Exhibit 59: Bayer AG - Business segments Exhibit 60: Bayer AG - Organizational developments Exhibit 61: Bayer AG - Geographic focus Exhibit 62: Bayer AG - Segment focus Exhibit 63: Bayer AG - Key offerings Exhibit 64: Bayer AG - Key customers Exhibit 65: Merck & Co. Inc. - Vendor overview Exhibit 66: Merck & Co. Inc. - Business segments Exhibit 67: Merck & Co. Inc. - Organizational developments Exhibit 68: Merck & Co. Inc. - Geographic focus Exhibit 69: Merck & Co. Inc. - Segment focus Exhibit 70: Merck & Co. Inc. - Key offerings Exhibit 71: Merck & Co. Inc. - Key customers Exhibit 72: Novartis AG - Vendor overview Exhibit 73: Novartis AG - Business segments Exhibit 74: Novartis AG - Organizational developments Exhibit 75: Novartis AG - Geographic focus Exhibit 76: Novartis AG - Segment focus Exhibit 77: Novartis AG - Key offerings Exhibit 78: Novartis AG - Key customers Exhibit 79: Sanofi - Vendor overview Exhibit 80: Sanofi - Business segments Exhibit 81: Sanofi - Organizational developments Exhibit 82: Sanofi - Geographic focus Exhibit 83: Sanofi - Segment focus Exhibit 84: Sanofi - Key offerings Exhibit 85: Sanofi - Key customers Exhibit 86: Validation techniques employed for market sizing Exhibit 87: Definition of market positioning of vendors

AstraZeneca Plc, Bayer AG, Merck & Co. Inc., Novartis AG, and Sanofi.